Crystalline Salts of (4S, 4AS, 5AR, 12AS) -4-DIMETHYLAMINO-3,10,12,12A-TETRAHYDROXY-7 - [(METHOXY (METHYL) AMINO) -METHYL] -1,11-DIOXO-1,4 , 4A, 5.5A, 6,11,12A-OCTAHYDRO-NAPHTHACEN-2-CARBOXYLIC ACID AMIDE AND PROCEDURES FOR USING IT
A crystalline mono hydrochloride salt of (4S,4aS,5aR,12aS)-4-dimethylamino- 3,10, 12, 12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]- 1, 11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide is disclosed having improved stability. In addition, a crystalline mono mesylate salt and crystalline mono sulfate salt of (4S,4aS,5aR,12aS)-4-dimethyl-amino-3,10,12,12a-tetrahydroxy-7- [(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene- 2-carboxylic acid amide are also disclosed having improved stability. A pharmaceutical composition containing the crystalline salts and methods of treating inflammatory skin disorders and bacterial infections comprising administering the crystalline salts are also disclosed.
